Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Apr 9, 2009

Premium

Title: siRNA Targeting Myeloid Cell Leukemia Sequence 1

Number: 7,514,550

Filed: Sept. 20, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing of myeloid cell leukemia sequence 1 is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs directed to myeloid cell leukemia sequence 1 by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."


Title: Tumor Inhibition by Modulating Sprouty Expression or Activity

Number: 7,514,549

Filed: April 17, 2006

Lead Inventor: Justin McCormick, Michigan State University

The patent, its abstract states, claims "methods … for identifying compounds that decrease the expression or activity of an over-expressed Sprouty protein in certain cancers. Such compounds can be useful for treating cancers in which a Sprouty protein is over-expressed. Also provided are therapeutic formulations and pharmaceutical formulations [comprising an siRNA] for treating cancers characterized by over-expression of a Sprouty protein."


Title: Methods of Inhibiting COX-2

Number: 7,514,548

Filed: Aug. 1, 2005

Lead Inventor: Douglas Trask, University of Iowa

The invention, the patent's abstract states, comprises "RNA molecules [such as] antisense, RNAi, or siRNA … specific for COX-2, and further provides methods of reducing expression of COX-2 in cells, [for example], cancer cells."


Title: Carrier Peptide for Delivering siRNA in Mammalian Cells

Number:
7,514,530

Filed: April 26, 2004

Lead Inventor:
Gilles Divita, Centre National de la Recherche Scientifique

The invention, the patent's abstract states, comprises a peptide carrier and an "appropriate siRNA … selected to silence a target mRNA."


Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules

Number: 7,514,099

Filed: Feb. 14, 2006

Lead Inventor:
Tongqian Chen, Sirna Therapeutics (Merck)

According to the patent's abstract, the invention "relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid molecules … [and] also features compositions and methods of use for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity in a subject or organism.

"Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles, and transfection agents that effectively transfect or deliver biologically active molecules, such as … dsRNA … and small nucleic acid molecules … to relevant cells and/or tissues, such as in a subject or organism. Such novel cationic lipids, microparticles, nanoparticles, and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism. The compositions described … are generally referred to as formulated molecular compositions or lipid nanoparticles," the abstract states.


Title: Self-Complementary AAV-Mediated Delivery of Interfering RNA Molecules to Treat or Prevent Ocular Disorders

Number: 20090087413

Filed: Oct. 1, 2008

Inventor:
Allan Shepard, Alcon

"The invention provides methods for delivering interfering RNA molecules to an eye of a patient to treat ocular disorders," the patent application's abstract states. "In particular, the methods of the invention comprise the use of a self-complementary adeno-associated viral vector that can deliver an interfering RNA molecule to an eye of a patient to inhibit expression of a gene that is associated with an ocular disorder."


Title: Two-Color Real-Time/End-Point Quantitation of microRNAs

Number: 20090087858

Filed: Dec. 8, 2008

Lead Inventor: Andrew Finn, Applied Biosystems

The invention, the patent application's abstract states, "is directed to methods, reagents, kits, and compositions for detecting target polynucleotide sequences, especially small target polynucleotides such as miRNAs, between two samples. A pair of linker probes can be employed in two different reactions to query a particular species of target polynucleotide. A pair of detector probes, a single forward primer specific for the target polynucleotide, and a reverse primer can be employed in an amplification reaction to query the difference in expression level of the target polynucleotide between the two samples.

"In some embodiments a plurality of small miRNAs are queried with a plurality of linker probes," the abstract adds. "The plurality of queried miRNAs can then be decoded in a plurality of amplification reactions."



Title:
Primer Extension-Based Method for the Generation of siRNA/miRNA Expression Vectors

Number: 20090087910

Filed: Aug. 15, 2008

Lead Inventor: Lin Liu, Oklahoma State University

"Functional shRNA is produced from an expression vector prepared by selecting a two primer design in which the primers are less than about 50 nucleotides in length, annealing and extending the primers using primer extension, digesting the primer extension product and inserting the digestion product into a suitable vector," the patent application's abstract states. "When the shRNA vectors are inserted into a cell, shRNA transcribed from the vectors modulates gene activity within the cell."


Title: siRNA Targeting Transducin Beta-Like 3

Number: 20090088563

Filed: Oct. 14, 2008

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TBL3."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.